Want to see DVA full AI Analyst Report?
Revenue by Segment
Breaks down income across different business areas, showing where the company is earning the most and identifying growth or risk areas.Dialysis remains the revenue backbone with steady, incremental growth, but ancillary services are the standout — accelerating sharply since late‑2023 and now driving outsized top‑line and margin upside. Management’s Q1 beat, raised guidance and IKC performance validate that ancillary and per‑treatment revenue momentum can offset modest treatment volume weakness. Key risks: rising G&A from tech/AI investments, ACA mix pressure and treatment variability could temper full‑year RPT and margin upside despite the favorable secular shift toward ancillary growth.
Date | Eliminations | Dialysis | Ancillary Services |
|---|---|---|---|
Jun 30, 2026 | -$14.00M | $3.01B | $557.00M |
Mar 31, 2026 | -$24.00M | $2.94B | $498.00M |
Dec 31, 2025 | -$23.00M | $3.08B | $567.00M |
Sep 30, 2025 | -$14.70M | $2.98B | $454.89M |
Jun 30, 2025 | -$20.00M | $2.91B | $486.00M |
Mar 31, 2025 | -$14.00M | $2.82B | $415.00M |
Dec 31, 2024 | -$23.00M | $2.89B | $430.00M |
Sep 30, 2024 | -$19.00M | $2.91B | $376.00M |
Jun 30, 2024 | -$17.00M | $2.84B | $362.00M |
Mar 31, 2024 | -$27.00M | $2.76B | $342.00M |